US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

2.34

-0.3050-11.55%

Post-market: 2.31-0.0250-1.07%16:22 EDT

Volume:542.94K

Turnover:1.29M

Market Cap:77.51M

PE:-0.75

High:2.68

Open:2.53

Low:2.27

Close:2.64

Loading ...

Overview Company News Filings

Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment

BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference

Lexeo Therapeutics Announces Positive Interim Data for Lx1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of Apoe4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS

Lexeo Therapeutics - Sees Further Lx1001 Development Plans in 2025

THOMSON REUTERS

Lexeo Therapeutics Inc - Lx1001 Well Tolerated With No Reports of Aria

THOMSON REUTERS

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy Rating

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LXEO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":2.335,"timestamp":1743796800000,"preClose":2.64,"halted":0,"volume":542944,"hourTrading":{"tag":"盘后","latestPrice":2.31,"preClose":2.335,"latestTime":"16:22 EDT","volume":2028,"amount":4733.1303396,"timestamp":1743798170333},"delay":0,"floatShares":21814872,"shares":33196997,"eps":-3.093449,"marketStatus":"Post-Market Trading","change":-0.305,"latestTime":"04-04 16:51:07 EDT","open":2.53,"high":2.68,"low":2.2668,"amount":1287460.214679,"amplitude":0.156515,"askPrice":3.77,"askSize":200,"bidPrice":2.3,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.093449,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743811200000},"marketStatusCode":4,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":2.64,"preHourTrading":{"tag":"盘前","latestPrice":2.5,"preClose":2.64,"latestTime":"08:19 EDT","volume":3404,"amount":8510,"timestamp":1743769176436},"postHourTrading":{"tag":"盘后","latestPrice":2.31,"preClose":2.335,"latestTime":"16:22 EDT","volume":2028,"amount":4733.1303396,"timestamp":1743798170333},"volumeRatio":1.098967,"impliedVol":1.3232,"impliedVolPercentile":0.4557},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":21814872,"roa":"-46.11%","roe":"-85.37%","lyrEps":-3.093449,"volumeRatio":1.098967,"shares":33196997,"dividePrice":0,"high":2.68,"amplitude":0.156515,"preClose":2.64,"low":2.2668,"week52Low":2.2668,"pbRate":"0.66","week52High":19.5,"institutionHeld":0,"latestPrice":2.335,"committee":-0.333333,"eps":-3.093449,"divideRate":0,"volume":542944,"delay":0,"ttmEps":-3.093449,"open":2.53,"prevYearClose":6.58,"prevWeekClose":4.1,"prevMonthClose":3.47,"prevQuarterClose":3.47,"fiveDayClose":4.1,"twentyDayClose":2.7,"sixtyDayClose":7.33},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2479031692","title":"Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2479031692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479031692?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:26","pubTimestamp":1730287560,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.\"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said.The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.\"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.The data were presented at th","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479727672","title":"BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479727672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479727672?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:53","pubTimestamp":1730285595,"startTime":"0","endTime":"0","summary":"Oct 30  - Lexeo Therapeutics Inc   :   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE  CONFERENCE   * LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA   * LEXEO THERAPEUTICS  - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENE","BK4121","LXEO","BK4139"],"gpt_icon":0},{"id":"2479760452","title":"Lexeo Therapeutics Announces Positive Interim Data for Lx1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of Apoe4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479760452?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2479536279","title":"Lexeo Therapeutics  - Sees Further Lx1001 Development Plans in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2479536279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479536279?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479279819","title":"Lexeo Therapeutics Inc - Lx1001 Well Tolerated With No Reports of Aria","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479279819?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA1S9XNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479271966","title":"Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479271966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479271966?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":"Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of particip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2971504/0/en/Lexeo-Therapeutics-Announces-Positive-Interim-Data-for-LX1001-First-Ever-Gene-Therapy-to-Impact-the-Underlying-Genetic-Cause-of-APOE4-Associated-Alzheimer-s-Disease-at-the-Clinical.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CSF","ARIA","LXEO","MCI","BK4139","GENE"],"gpt_icon":0},{"id":"2478578965","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2478578965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478578965?lang=en_us&edition=fundamental","pubTime":"2024-10-26 03:34","pubTimestamp":1729884840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 15:34 ET (19:34 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2478373644","title":"Lexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2478373644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478373644?lang=en_us&edition=fundamental","pubTime":"2024-10-25 10:56","pubTimestamp":1729824975,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-alzheimers-treatment-advances-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-alzheimers-treatment-advances-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2477524380","title":"Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2477524380","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477524380?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:30","pubTimestamp":1729596600,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation to highlight safety and efficacy of LX1001 across four dose cohorts. NEW YORK, Oct. 22, 2024  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that interim data from the ongoing Phase 1/2 trial  of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer’s Disease  conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into thecentral nervous systemsof APOE4 homozygotes with Alzheimer’s disease.“APOE4-associated Alzheimer’s disease is a devastating, genetically distinct condition and despite recent therapeutic advances, patients with this genetic profile hav","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C6MfrF5RapjZGL3SUI9rGA--~B/aD0xNDgxO3c9Mzg0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1fb96273e5cd7873db2f9f2c6eaa0b39","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C6MfrF5RapjZGL3SUI9rGA--~B/aD0xNDgxO3c9Mzg0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1fb96273e5cd7873db2f9f2c6eaa0b39"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexeo-therapeutics-present-interim-data-113000808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXEO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":49}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1718251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2025-04-03","current":-0.994225,"percent":0.990991,"low":-8.903248,"twenty":-6.339477,"median":-4.815798,"eighty":-2.486552,"high":-0.893823,"avg":-4.573986,"sd":1.990892,"marketCap":97765156},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-03","current":-0.994225,"twenty":-6.339477,"median":-4.815798,"eighty":-2.486552,"marketCap":97765156}],"updateTime":1743799867209}}}